Tri Locum Partners’s Neurogene NGNE Stock Holding History

Tri Locum Partners’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-512	Closed	-$5K	–	71
2022 Q4	$5K	Buy	+512	New	+$5.29K	﹤0.01%	73

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tri Locum Partners's NGNE Position: Q1 2023 in Review

Tri Locum Partners sold out of Neurogene (NGNE) in Q1 2023, closing a stake of 512 shares — an estimated $5K sold.

Tri Locum Partners first reported a position in NGNE in Q4 2022 and held it in 1 quarter. The position peaked at $5K in Q4 2022. 39 funds tracked by Wall St. Rank hold NGNE as of Q1 2023.

Tri Locum Partners reported no remaining Neurogene position as of Q1 2023 after selling out during the quarter.
Tri Locum Partners sold 512 Neurogene shares in Q1 2023, an estimated $5K.
Tri Locum Partners first reported a position in Neurogene in Q4 2022 and held it in 1 quarter.
Tri Locum Partners's Neurogene position peaked at $5K in Q4 2022.
39 funds tracked by Wall St. Rank held Neurogene as of Q1 2023.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.